{
    "clinical_study": {
        "@rank": "25289", 
        "brief_summary": {
            "textblock": "OBJECTIVES:\n\n      I.  Assess the safety and efficacy of recombinant human insulin-like growth factor 1 in a\n      patient with Werner's syndrome and osteoporosis."
        }, 
        "brief_title": "Descriptive Study of Recombinant Human Insulin-Like Growth Factor for Osteoporosis in Werner's Syndrome", 
        "condition": "Werner's Syndrome", 
        "condition_browse": {
            "mesh_term": "Werner Syndrome"
        }, 
        "detailed_description": {
            "textblock": "PROTOCOL OUTLINE: The patient receives subcutaneous recombinant human insulin-like growth\n      factor 1 daily for 7 months.  The dose is adjusted according to the serum hormone level and\n      biological markers of bone turnover.\n\n      Concurrent therapy includes a metabolic diet, calcium citrate, and estradiol."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "PROTOCOL ENTRY CRITERIA:\n\n        --Disease Characteristics-- Werner's syndrome with osteoporosis and low serum insulin-like\n        growth factor 1 level Patient treated on protocol 04-9215300 \"Metabolic and Skeletal\n        Effects of Exogenous Recombinant Human Insulin-Like Growth Factor\""
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": "1", 
        "firstreceived_date": "February 24, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00004815", 
            "org_study_id": "199/12024", 
            "secondary_id": "UTSMC-49215300"
        }, 
        "intervention": {
            "intervention_name": "growth hormone", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Hormones"
        }, 
        "keyword": [
            "Werner's syndrome", 
            "genetic diseases and dysmorphic syndromes", 
            "rare disease"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "overall_official": {
            "affiliation": "University of Texas", 
            "last_name": "Craig D. Rubin", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00004815"
        }, 
        "source": "Office of Rare Diseases (ORD)", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)", 
                    "agency_class": "NIH"
                }, 
                {
                    "agency": "University of Texas", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "National Center for Research Resources (NCRR)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "May 1992", 
        "study_design": "Allocation: Non-Randomized, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2004"
    }, 
    "geocoordinates": {}
}